Rakuten Medical, Inc., a worldwide biotechnology firm focused on developing and commercializing precision, cell-targeting Alluminox platform-based photoimmunotherapy, declared the launch of its global multi-regional phase 3 clinical trial...
Jaguar Health, Inc. (Jaguar) affiliated companies Napo Pharmaceuticals (Napo) and Napo Therapeutics announced that the first patient has received a dose in the independent investigator-led POC trial of crofelemer, Jaguar's innovative plant-derived...
ENA Respiratory, a clinical-stage pharmaceutical firm focused on creating antiviral host defense immune boosters to reduce the effects of viral respiratory infections in vulnerable groups, reports that it has successfully finalized dosing for the...
Tris Pharma, Inc. (Tris), a biopharmaceutical company in the commercial stage, revealed encouraging topline findings from its ALLEVIATE-1 crucial Phase 3 clinical trial assessing cebranopadol, an experimental treatment, for addressing moderate-to...
Guangzhou Fermion Technology Co., Ltd., an AI-focused biotech firm in clinical development, and Simcere Pharmaceutical Group Limited, a pharmaceutical entity, have announced a collaboration to advance a clinical-stage pain treatment asset, FZ002...
PulseSight Therapeutics SAS, a biotech firm focused on ophthalmology that creates groundbreaking non-viral vector therapies utilizing minimally-invasive delivery methods, has announced it has filed a Clinical Trial Authorization (CTA) with the...
Lyndra Therapeutics, a biopharmaceutical company in the clinical stage, has formed a strategic partnership with Thermo Fisher Scientific Inc., wherein Thermo Fisher will offer global clinical research and commercial manufacturing services to...
ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...
CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor...
.jpg)
, CDSCO.jpg)